Details of the Drug Combination

General Information of Drug Combination (ID: DCEUHY4)

• Drug Combination Name: Paritaprevir + ABT-333
• Indication: Chronic Hepatitis C; Status: Phase 2 [1]
• Component Drugs:
  Paritaprevir (DM4N7BT): Small molecular drug
  ABT-333 (DM7TOWX): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Paritaprevir

Disease Entry	ICD 11	Status	REF
Hepatitis C	1E51	Approved	[2]

Paritaprevir Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Indication(s) of ABT-333

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 1	[3]

ABT-333 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)	TTMVBWH	POLG_HCV1	Inhibitor	[3]

ABT-333 Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

ABT-333 Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[5]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[5]

References

• [1] ClinicalTrials.gov (NCT01464827) ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
• [4] Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
• [5] Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.